Compare CubeSmart (CUBE) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CubeSmart vs Vertex Pharmaceuticals Incorporated — how do they compare? CubeSmart trades at $40.56 (market cap $9.19B), while Vertex Pharmaceuticals Incorporated trades at $477.46 (market cap $121.89B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 13.3× CubeSmart's market cap, and CubeSmart pays a 5.22% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| CUBE | VRTX | |
|---|---|---|
Market Cap | $9.19B | $121.89B |
Sector | Real Estate | Health |
52-Week High | $42.34 | $529.59 |
52-Week Low | $35.36 | $366.54 |
Enterprise Value | $12.69B | $116.63B |
Dividend Yield | 5.22% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CubeSmart
CubeSmart is a real estate investment trust that acquires, owns, and manages self-storage facilities throughout the United States. The company's real estate portfolio is composed of buildings with numerous enclosed storage areas for both residential and commercial customers to rent mainly on a month-by-month basis. Most of CubeSmart's facilities are located in Florida, Texas, California, New York, and Illinois. Cumulatively, these states account for both the majority of the square footage in the company's real estate portfolio and the majority of its revenue. CubeSmart derives nearly all of its revenue from rental income from tenants utilizing its storage facilities.
Read more on CUBE →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
